Table 3.
Characteristics of tyrosine kinase inhibitor-treated patients with and without pulmonary hypertension.
| With PH (N = 12) | Without PH (N = 100) | P ∗ | |
| Age, y, median (range) | 66.5 (58−78) | 57.5 (13−81) | .001 |
| Female, N (%) | 5 (41.7) | 41 (41.0) | 1.00 |
| Palpable splenomegaly at CML diagnosis, N (%) | 4 (33.3) | 36 (36.0) | 1.00 |
| Hematologic indices at CML diagnosis | |||
| WBC (×109/L) | 113.8 ± 101.3 | 143.2 ± 109.7 | .40 |
| Hemoglobin (g/dL) | 11.3 ± 2.0 | 10.8 ± 2.3 | .48 |
| Platelet (×109/L) | 761.6 ± 853.0 | 589.0 ± 448.1 | .28 |
| Phase at the time of TTE examined, N (%) | .80 | ||
| Chronic phase | 11 (91.7) | 99 (99.0) | |
| Accelerated phase | 1 (8.3) | 1 (1.0) | |
| Sokal score, N (%) | .71 | ||
| Low risk | 2 (16.7) | 28 (28.0) | |
| Intermediate risk | 5 (41.7) | 43 (43.0) | |
| High risk | 5 (41.7) | 29 (29.0) | |
| Hasford score, N (%) | .24 | ||
| Low risk | 0 (0.0) | 28 (28.0) | |
| Intermediate risk | 8 (66.7) | 56 (56.0) | |
| High risk | 4 (33.3) | 16 (16.0) | |
| ETLS, N (%) | .93 | ||
| Low risk | 10 (83.3) | 88 (88.0) | |
| Intermediate risk | 2 (16.7) | 11 (11.0) | |
| High risk | 0 (0.0) | 1 (1.0) | |
| TKI treated at the time of TTE examined, N (%) | |||
| Imatinib | 3 (25.0) | 37 (37.0) | .53 |
| Nilotinib | 1 (8.3) | 34 (34.0) | .10 |
| Dasatinib | 8 (66.7) | 29 (29.0) | .01 |
| Line of TKI at the time of TTE examined, N (%) | .27 | ||
| First | 9 (75.0) | 77 (77.0) | |
| Second | 1 (8.6) | 18 (18.0) | |
| Third | 2 (16.7) | 4 (4.0) | |
| Fourth or more | 0 (0.0) | 1 (1.0) | |
| Time receiving any TKI(s) (months) | 40.0 ± 36.1 | 48.2 ± 36.0 | .40 |
| Comorbidity, N (%) | |||
| Diabetes mellitus | 4 (66.7) | 14 (14.0) | .10 |
| Hypertension | 6 (50.0) | 22 (22.0) | .07 |
| Smoking | 2 (16.7) | 15 (15.0) | .81 |
| Ischemic heart disease | 1 (8.7) | 2 (2.0) | .33 |
| Chronic kidney disease | 7 (58.3) | 16 (16.0) | .003 |
| Reason for undergoing TTE, N (%) | .001 | ||
| Cardiopulmonary symptoms or signs | 7 (58.3) | 3 (3.0) | |
| Screening for PH | 5 (41.7) | 87 (87.0) | |
| Others | 0 (0.0) | 10 (10.0) | |
ETLS = EUTOS long-term survival score, PH = pulmonary hypertension, TKI = tyrosine kinase inhibitor, TTE = transthoracic echocardiography.
∗
χ2 Test, Fisher exact test, or student t test.